On 29 May 2019, orphan designation (EU/3/19/2160) was granted by the European Commission to RHEACELL GmbH & Co. KG, Germany, for allogeneic skin-derived ABCB5-positive mesenchymal stem cells (also known as allo-APZ2-EB) for the treatment of epidermolysis bullosa.
Allogeneic skin-derived ABCB5-positive mesenchymal stem cells
Treatment of epidermolysis bullosa
|Date of designation||
|Orphan designation status||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: